Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma.
Chen W, Zhang H, Chen Z, Jiang H, Liao L, Fan S, Xing J, Xie Y, Chen S, Ding H, Chen K, Jiang H, Luo C, Zheng M, Yao Z, Huang Y, Zhang Y.
Chen W, et al. Among authors: jiang h.
Oncogenesis. 2018 Nov 2;7(11):83. doi: 10.1038/s41389-018-0093-z.
Oncogenesis. 2018.
PMID: 30385738
Free PMC article.